GeoVax Labs is a biotechnology company focused on the development of vaccines for diseases caused by HIV. The company’s vaccines are unique in expressing virus-like particles displaying the trimeric membrane-bound form of the HIV-1 envelope glycoprotein. Presently in Phase I testing, the company’s second-generation preventive vaccine is planned to progress to Phase 2 efficacy testing. In various doses and combinations, GeoVax’s vaccine has been tested in around 500 people. For more information, visit the company’s Web site at www.geovax.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: